Covid-19 Vaccine Covishield Update: Permission sought from DCGI for second and third phase trials of vaccine
The Serum Institute of India has sought permission from the Drugs Controller General of India (DCGI) for human trials of the Corona vaccine developed by Oxford University and AstraZeneca. Vaccine manufacturers expect the vaccine to hit the market by this month.
The Serum Institute of India has sought permission from the Drugs Controller General of India (DCGI) for Phase II and Phase III trials of the corona vaccine developed by Oxford University and AstraZeneca. Sources said the Pune-based drug firm submitted its application to DCGI on Friday and sought permission to test ‘Kovishield’. According to the application, it will conduct a test to determine the safety and immunogenicity of ‘covishield’ (COVID-19) in healthy Indian adults.
People of this age can be involved in trials
The firm said that about 1,600 people over the age of 18 could participate in this test. To market the vaccine, SII, the world’s largest vaccine manufacturer, has collaborated with the British-Swedish pharma company Astraeneneca to produce a potential vaccine developed by the Jenner Institute (Oxford University) according to the number produced and sold. An agreement has been signed.
It has been claimed
On the partnership with AstraZeneca, Adar Poonawalla, CEO of Serum Institute of India had said, “Serum Institute of India has teamed up with AstraZeneca to produce and supply 1 billion doses of the COVID-19 vaccine being developed by Oxford University Has entered into a manufacturing partnership. ” He said that these vaccines would be for middle and low income countries (GAVI countries) in India and around the world.
The firm plans to begin Phase 2 and 3 human trials in India in August. Oxford University announced satisfactory progress with the vaccine on Monday, making it one of dozens of vaccine candidates to be developed worldwide. According to a Lancet report, preliminary test results showed that the vaccine is safe and indicates a protective immune response.
There are no comments at the moment, do you want to add one?
Write a comment